Vancouver, Canada-based Lungpacer Medical Inc. raised US$20 million of Series B venture funding from WJFS and its existing lead investor 4CGE.
Lungpacer develops a diaphragm pacing therapy system (DPTS) to assist in weaning patients off mechanical ventilation who are determined by a healthcare provider to be at high risk of weaning failure.
Fasken represented Lungpacer Medical with a team led by Jon Conlin and included Steven Lumbala (Corporate Finance).
Lungpacer develops a diaphragm pacing therapy system (DPTS) to assist in weaning patients off mechanical ventilation who are determined by a healthcare provider to be at high risk of weaning failure.
Fasken represented Lungpacer Medical with a team led by Jon Conlin and included Steven Lumbala (Corporate Finance).
Jurisdiction
- British Columbia
